Clinical trial NCT06725953: Remote Physical Activity Programming to Improve Outcomes in Cancer Survivors With and Without Type 2 Diabetes
Official title: Cerebrovascular, Cognitive, Pro-Inflammatory, and Cardiometabolic Outcomes in Cancer Survivors With and Without Type II Diabetes Reporting Chemo-Brain: Baseline Differences and Impact of Activity
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cancer Survivorship
Chemotherapy Side Effects
Keywords: Aerobic Physical Activity
Resistance Training
Wearable Devices
Smartphone Applications
Cancer Survivors
Chemo-Brain
Health Outcomes
Lead sponsor: University of Oklahoma
Sponsor class: OTHER
First posted: 2024-12-10
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Social Cognitive Theory-based, Technology-delivered Physical Activity Program
Primary purpose: SUPPORTIVE_CARE

Brief summary: The growing U.S. cancer survivor population is projected to hit 26M by 2040. Chemotherapy represents an effective cancer treatment but can diminish cancer survivors' quality of life-particularly cognitive function-through select pathophysiological processes. Research on chemotherapy-induced cognitive impairment (hereafter, 'chemo-brain') is therefore critical. Chemotherapy disrupts immune system function and antioxidant regulation, causing inflammatory molecule release and damaging the brain's blood vessels. The brain's vascular function and, possibly, its neurons, are subsequently impaired-likely contributing to chemo-brain. Type 2 diabetes (T2D), a common cancer survivor comorbidity, shares underlying pathophysiology with chemo-brain. T2D-related insulin resistance can precipitate repeated high blood sugar episodes which increase inflammatory molecule release. In individuals with T2D without cancer, negative relationships are observed between inflammatory molecule concentrations and the brain's vascular and/or cognitive function. Cancer survivors with T2D might thus have higher chemo-brain risk than those without T2D. Yet, more research must compare how the brain's vascular function, as well as cognitive, inflammatory, and cardiometabolic indices, differ between these groups. Physical activity (PA) counteracts chemo-brain's and T2D's pathophysiology, with higher PA/fitness resulting in better vascular function of the brain, lower inflammatory molecule concentrations, and improved insulin sensitivity. We are therefore conducting a 30-participant quasi-experimental pilot study in cancer survivors with (cases) and without (controls) T2D. We will first investigate between-group differences in the brain's vascular function as well as cognitive, inflammatory, cardiometabolic, and epigenetic outcomes. We will then examine between-group changes in these outcomes and select psychosocial metrics during a 12-week technology-based PA program-potentially further elucidating involved mechanisms.

Detailed description: While incident cancer cases of any site remain stable, 5-year cancer survival rates have increased. In January 2022, \>18M individuals in the U.S. were CS-reflecting those diagnosed with cancer until death-with a projected increase to 26M by 2040. Although modern cancer treatments are effective, these treatments can worsen CS HRQoL. Several cancer treatments-most notably, chemotherapy-are associated with cognitive difficulties. While chemotherapy effectively treats many malignancies, it also negatively impacts vascular endothelial cells-leading to pathophysiological processes contributing to CS's oft-reported 'chemo-brain' during/after treatment. As CS populations grow, CICI mitigation research is crucial to improve HRQoL.

CICI likely occurs for several reasons. Chemotherapy can induce immune and antioxidant dysregulation. This dysregulation can lead to peripheral pro-inflammatory cytokines being released which damage and cross the blood-brain barrier-contributing to central pro-inflammatory cytokine release and causing neuroinflammation-related impairments in neurogenesis and the myelination process. Endothelial dysfunction and cerebral autoregulation failure can also result from this damage. Reviews suggest these mechanisms alter cerebrovascular function more broadly by impairing cerebral perfusion, glucose metabolism, and angiogenesis; thus contributing to CICI. T2D is both a risk factor for developing several common cancers and, given its prevalence, a common CS comorbidity heightening cancer recurrence risk. Several pathophysiological mechanisms underlying CICI are observed with T2D. Insulin resistance can result in repeated hyperglycemic episodes and subsequent pro-inflammatory cytokine elevation-possibly explaining why insulin resistance is correlated with diminished cerebrovascular and cognitive function in individuals with T2D. This might also explain why, in newly diagnosed CS with pro-inflammatory comorbidities (e.g., T2D), higher pro-inflammatory cytokines and poorer cognitive function have been observed relative to CS without comorbidities-even prior to chemotherapy. CICI mitigation research should thus focus on CS most vulnerable to CICI (e.g., CS with T2D).

Aerobic PA and resistance training (RT) have robust health benefits counteracting much of the pathophysiology underlying CICI and T2D. Reviews suggest better cerebrovascular function in those who are more active and/or fitter relative to those less active and/or fit, with greater fitness positively associated with cognitive function in other at-risk populations. In those with T2D, research has shown that PA is impactful at lowering pro-inflammatory cytokines and improving insulin sensitivity. Yet, research is needed on how increasing PA in CS with T2D reporting CICI improves cerebrovascular and cognitive health through improved fitness.

We are thus conducting a 30-participant quasi-experimental pilot study in CS+T2D (n=15; cases) and CS (n=15; controls)-all self-reporting CICI. We will first investigate cerebrovascular, cognitive, pro-inflammatory, cardiometabolic, and epigenetic (exploratory) differences between CS+T2D and CS given that no known investigations have directly compared these outcomes concurrently between these groups (Aim 1). We will then examine differential between-group changes in these outcomes and select psychosocial metrics during a 12-week technology-delivered PA program grounded in the Social Cognitive Theory-crucial to further investigate how to intervene and reverse the underlying pathophysiology (Aims 2 and 3). This collaboration between clinical scientists and translational researchers is critical to conducting this comprehensive project given our diverse skillsets and preliminary studies. This collaboration will serve our larger goal of acquiring extramural funding to investigate in even greater detail the most clinically-relevant pathophysiological mechanisms observed during this project. Our Aims/Hypotheses are (main outcomes underlined):

Aim 1: Characterize cerebrovascular function, cognitive function, pro-inflammatory cytokines, and cardiometabolic outcome differences between CS+T2D and CS. Our Hypotheses 1 are that CS+T2D will have a: poorer measures of middle cerebral artery velocity and cerebrovascular conductance, reactivity, and resistance. b: lower executive function scores. c: higher c-reactive protein, interleukin-6, and monocyte chemoattractant protein 1 concentrations. and d: higher blood pressure and insulin resistance measures.

Aim 2: Examine pre- to post-PA program differences for changes in A1's cerebrovascular function, cognitive function, pro-inflammatory cytokines, and cardiometabolic outcomes between CS+T2D and CS. Hypothesis 2: We will observe greater pre- to post-PA program improvements in these outcomes for CS+T2D relative to CS.

Aim 3: Assess pre- to post-PA program differences for changes in Social Cognitive Theory (SCT)-based constructs, select psychosocial outcomes, HRQoL, and PA between CS+T2D and CS. Our Hypotheses 3 are that CS+T2D and CS will have similar improvements in a: SCT-based, PA-related self-efficacy, outcome expectancy, enjoyment, social support, and barriers and b: stress, anxiety, mood, and depressive symptoms but that CS+T2D will have greater improvements than CS in c: HRQoL due to greater improvements in physical functioning and pain intensity/interference and d: overall PA participation due to greater increases in light and moderate PA.

Exploratory Aim: Characterize epigenetic markers of biologically-relevant pathways related to neurocognition, energy metabolism, and/or T2D among CS+T2D and CS as well as whether changes are observed in these markers pre- to post-PA program. Exploratory Hypothesis: Distinct epigenetic profiles will be evident between CS+T2D and CS, with both groups experiencing pre- to post-PA program changes in these profiles.

Eligibility criteria: Inclusion Criteria:

1. ≥18 years old
2. ability to speak/read English
3. ability to provide informed consent
4. underwent treatment within the last three years for a non-central nervous system-related cancer with said treatment having included chemotherapy
5. self-reported cognitive difficulties following cancer treatment
6. For CS+T2D: current T2D diagnosis as classified by a fasted blood glucose of ≥126 mg/dL, 2-hour oral glucose tolerance test of ≥200 mg/dL, HbA1c level of ≥6.5%, or use of medications to treat hyperglycemia (e.g., Metformin) or For CS: no current T2D diagnosis as classified by a fasted blood glucose \<100 mg/dL, 2-hour oral glucose tolerance test \<140 mg/dL, or HbA1c level of \<5.7%. Presence/absence of T2D to be confirmed preferentially via physician's documentation
7. own smartphone and/or computer with internet access
8. willing to participate in the 12-week remotely-delivered PA program

Exclusion Criteria:

1. reporting a Physical Activity Readiness Questionnaire (2017 PAR-Q) score that indicates PA may potentially be unsafe, unless the participant produces a signed doctor's note. We will define 2017 PAR-Q+ scores as indicating that PA may potentially be unsafe as responding "Yes" to any of the follow-up questions except \[1\] if the individual indicates that they have high blood pressure but subsequent responses indicate that they do not have problems keeping it under control and that their resting blood pressure is less than 160/90 mmHg, and \[2\] if the individual indicates that they have a metabolic condition but subsequent responses indicate that they do not have problems controlling their blood sugar levels, do not any experience signs or symptoms of hypoglycemia, and do not have any signs of symptoms of listed diabetes complications)
2. engaging in ≥75 min/week of vigorous-intensity PA, ≥150 min/week of moderate-intensity PA, or an equivalent combination of both over the last 3 months
3. currently a prisoner, pregnant, or planning to become pregnant during study.

Primary outcomes:
measure: Middle Cerebral Artery Velocity
timeFrame: Baseline and After Study Week 12
measure: Cerebrovascular Resistance
timeFrame: Baseline and After Study Week 12
measure: Cerebrovascular Conductance
timeFrame: Baseline and After Study Week 12
measure: Cerebrovascular Pulsatility
timeFrame: Baseline and After Study Week 12
measure: Dynamic Cerebral Autoregulation
timeFrame: Baseline and After Study Week 12
measure: Cognitive Function
timeFrame: Baseline and After Study Week 12
Secondary outcomes:
measure: Blood Pressure
timeFrame: Baseline and After Study Week 12
measure: Body Mass Index
timeFrame: Baseline and After Study Week 12
measure: Waist-to-Hip Ratio
timeFrame: Baseline and After Study Week 12
measure: Cholesterol Levels
timeFrame: Baseline and After Study Week 12
measure: Fasting Blood Glucose
timeFrame: Baseline and After Study Week 12
measure: Interleukin-6
timeFrame: Baseline and After Study Week 12
measure: Monocyte Chemoattractant Protein 1
timeFrame: Baseline and After Study Week 12
Other outcomes:
measure: Self-Efficacy for Physical Activity
timeFrame: Baseline, After Study Week 6, and After Study Week 12
measure: Social Support for Physical Activity
timeFrame: Baseline, After Study Week 6, and After Study Week 12
measure: Enjoyment of Physical Activity
timeFrame: Baseline, After Study Week 6, and After Study Week 12
measure: Barriers to Physical Activity
timeFrame: Baseline, After Study Week 6, and After Study Week 12
measure: Outcome Expectations of Physical Activity
timeFrame: Baseline, After Study Week 6, and After Study Week 12
measure: Perceived Stress
timeFrame: Baseline, After Study Week 6, and After Study Week 12
measure: Perceived Anxiety
timeFrame: Baseline, After Study Week 6, and After Study Week 12
measure: Mood
timeFrame: Baseline, After Study Week 6, and After Study Week 12
measure: Depressive Symptoms
timeFrame: Baseline, After Study Week 6, and After Study Week 12
measure: Health-related Quality of Life
timeFrame: Baseline, After Study Week 6, and After Study Week 12
measure: Overall Physical Activity
timeFrame: Baseline, After Study Week 6, and After Study Week 12
measure: Epigenetic Profile
timeFrame: Baseline and After Study Week 12
Locations:
city: Oklahoma City
country: United States
facility: University of Oklahoma Health Sciences
state: Oklahoma
Study officials:
affiliation: University of Oklahoma Health Sciences
name: Zachary C Pope, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Oklahoma, Department of Health and Exercise Science
name: Mikhail Kellawan, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Oklahoma Health Sciences
name: Andriy Yabluchanskiy, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: